# US 2026/0097000 A1 · Intranasal delivery of cannabinoids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097000 A1
- Document ID: US20260097000A1
- Status: Published application
- Kind: A1
- Application number: 19/111,969
- Filed: 2023-09-15
- Published: 2026-04-09
- Earliest claimed: 2022-09-16
- Assignees: Nanomerics LTD
- Applicants: Nanomerics Limited
- Inventors: Ijeoma UCHEGBU; Ilona KUBAJEWSKA; Andreas SCHATZLEIN
- Web page: https://patentgrep.com/patent/US20260097000A1

## CPC

- A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- A61K 9/0043: {Nose}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/22: Anxiolytics
- A61P 29/02: without antiinflammatory effect
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a method of treatment wherein a composition comprising a cannabinoid and an amphiphilic carbohydrate compound such as GCPQ is administered intranasally. The method of treatment is particularly suitable for use in central nervous system disorders. The invention further relates to the composition when formulated with other components in pharmaceutical compositions for use in therapy.

## Claims

### Claim 1

A method of treatment comprising administering to a human or animal a composition comprising a cannabinoid and an amphiphilic carbohydrate compound, wherein the composition is intranasally administered to the human or animal body.

### Claim 2

A composition comprising a cannabinoid and an amphiphilic carbohydrate compound for use in a method of treating a human or animal by intranasal administration.

### Claim 3 (depends on 1, 2)

The method or composition for use of claim 1 or 2 wherein the treatment is treatment of a disease of the central nervous system and is preferably epilepsy.

### Claim 4 (depends on 1, 2, 3)

The method or composition for use according to any of claims 1 to 3 wherein the treatment is of pain, anxiety or an autoimmune disease.

### Claim 5

A method or composition for use according to any preceding claim wherein the composition is in the form of nanoparticles.

### Claim 6 (depends on 5)

A method or composition for use according to claim 5 wherein the nanoparticles are processed to form nano-in-microparticles.

### Claim 7 (depends on 6)

A method or composition for use according to claim 6 wherein the composition is made by a process for forming nano-in-microparticles which is selected from spray-drying, lyophilisation, adding nanoparticles to powders to form granules, preferably wherein the process is spray-drying.

### Claim 8 (depends on 6, 7)

A method or composition for use according to claim 6 or 7 wherein the mean size of the nanoparticles in the nano-in-microparticles composition is under 1000 nm, preferably wherein the size of the nanoparticles is under 500 nm.

### Claim 9 (depends on 6, 7, 8)

A method or composition for use according to any one of claims 6 to 8 wherein the median volume distribution, D50, of the microparticles in the nano-in-microparticulate composition are between 5 to 30 μm, preferably between 10 to 25 μm.

### Claim 10 (depends on 9)

A method or composition for use according to claim 9 wherein less than 10% of particles are below 10 μm.

### Claim 11 (depends on 6, 7, 8, 9, 10)

A method or composition for use according to any one of claims 6 to 10 wherein the polydispersity of the nanoparticles within the nano-in-microparticles is less than 0.5, preferably less than 0.2, and more preferably less than 0.1.

### Claim 12 (depends on 6, 7, 8, 9, 10, 11)

A method or composition for use according to any one of claims 6 to 11 wherein the nanoparticles within the nano-in-microparticles are a colloidally stable formulation.

### Claim 13 (depends on 6, 7, 8, 9, 10, 11, 12)

A method or composition for use according to claim any one of claims 6 to 12 wherein the nano-in-microparticles are in the form of a dry powder.

### Claim 14 (depends on 13)

A method or composition for use according to claim 13 wherein the nano-in-microparticles are compatible with nasal spray devices.

### Claim 15 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method or composition for use according to any one of claims 6 to 14 wherein the nano-in-microparticles have a spherical, hollow or irregular morphology.

### Claim 16

A method or composition for use according to any preceding claim wherein the ratio of cannabinoid to amphiphilic carbohydrate compound is between 0.5:10 to 5:10 g g−1.

### Claim 17 (depends on 16)

A method or composition for use according to claim 16 wherein the ratio of cannabinoid to amphiphilic carbohydrate compound is 1:10 to 3:10 g g−1, preferably wherein the ratio is around 1:5 g g−1.

### Claim 18

A method or composition for use according to any preceding claim wherein the cannabinoid is delivered to the brain of the human or animal body.

### Claim 19

A method or composition for use according to any preceding claim wherein the cannabinoid is a non-psychoactive cannabinoid and is preferably cannabidiol.

### Claim 20

A method or composition for use according to any preceding claim wherein the amphiphilic carbohydrate compound is a chitosan derivative.

### Claim 21

A method or composition for use according to any preceding claim wherein the amphiphilic carbohydrate compound comprises the general formula:
wherein a+b+c+d=1.000 and
a is between 0.01 and 0.970
b is between 0.01 and 0.990,
c is between 0.0001 and 0.970, and
d is between 0.01 and 0.990;
and wherein:
X is a hydrophobic group;
R1, R2 and R3 are independently selected from a substituted or unsubstituted alkyl group;
R4, R5, R6 and R10 are independently selected from hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted ether group, or a substituted or unsubstituted alkene group;
R7 may be present or absent and, when present, is an unsubstituted or substituted alkyl group, an unsubstituted or substituted amine group or a substituted or unsubstituted amide group;
R3 and R9 are independently selected from hydrogen and either a substituted or unsubstituted alkyl group, a substituted or unsubstituted ether group, or a substituted or unsubstituted alkene group;
or a salt thereof.

### Claim 22 (depends on 21)

A method or composition for use according to claim 21 wherein the amphiphilic carbohydrate compound is quaternary ammonium palmitoyl glycol chitosan (GCPQ).

### Claim 23

A pharmaceutical composition suitable for intranasal administration comprising an amphiphilic carbohydrate compound and a non-psychoactive cannabinoid and one or more pharmaceutically acceptable excipients.

### Claim 24 (depends on 23)

A pharmaceutical composition according to claim 23 wherein the cannabinoid is selected from the group consisting of cannabidiol (CBD), cannabigerol (CBG), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabichromene (CBC) and combinations thereof.

### Claim 25 (depends on 24)

A pharmaceutical composition according to claim 24 wherein the cannabinoid is cannabidiol (CBD).

### Claim 26 (depends on 23, 24, 25)

A pharmaceutical composition according to any of claims 23 to 25 wherein the excipient is selected from the group consisting of tonicity enhancers, preservatives, solubilisers, non-toxic excipients, demulcents, sequestering agents, pH adjusting agents, co-solvents, viscosity building agents and combinations thereof.

### Claim 27 (depends on 23, 24, 25, 26)

A pharmaceutical composition according to any of claims 23 to 26 wherein the amphiphilic carbohydrate compound is GCPQ.

### Claim 28 (depends on 23, 24, 25, 26, 27)

A pharmaceutical composition according to any of claims 23 to 27 wherein the composition is in the form of nanoparticles.

### Claim 29 (depends on 28)

A pharmaceutical composition according to claim 28 wherein the nanoparticles are processed to form nano-in-microparticles.

### Claim 30 (depends on 28, 29)

A pharmaceutical composition according to claim 28 or 29 wherein the mean size of the nanoparticles in the nano-in-microparticles composition are under 1000 nm, preferably wherein the size of the nanoparticles is under 500 nm.

### Claim 31 (depends on 28, 29, 30)

A pharmaceutical composition according to any one of claims 28 to 30 wherein the median volume distribution, D50, of the microparticles in the nano-in-microparticulate composition are between 5 to 30 μm, preferably between 10 to 25 μm.

### Claim 32 (depends on 31)

A pharmaceutical composition according to claim 31 wherein less than 10% of particles are below 10 μm.

### Claim 33 (depends on 29, 30, 31, 32)

A pharmaceutical composition according to any one of claims 29 to 32 wherein the polydispersity of the nanoparticles within the nano-in-microparticles is less than 0.5, preferably less than 0.2, and more preferably less than 0.1.

### Claim 34 (depends on 29, 30, 31, 32, 33)

A pharmaceutical composition according to any one of claims 29 to 33 wherein the nanoparticles within the nano-in-microparticles are a colloidally stable formulation.

### Claim 35 (depends on 29, 30, 31, 32, 33)

A pharmaceutical composition according to claim any one of claims 29 to 33 wherein the nano-in-microparticles are in the form of a dry powder.

### Claim 36 (depends on 35)

A pharmaceutical composition according to claim 35 wherein the nano-in-microparticles are compatible with nasal spray devices.

### Claim 37 (depends on 29, 30, 31, 32, 33, 34, 35, 36)

A pharmaceutical composition according to any one of claims 29 to 36 wherein the nano-in-microparticles have a spherical morphology.

### Claim 38 (depends on 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

A pharmaceutical composition according to any one of claims 23-37 wherein the ratio of cannabinoid to amphiphilic carbohydrate compound is between 0.5:10 to 5:10 g g−1.

### Claim 39 (depends on 38)

A pharmaceutical composition according to claim 38 wherein the ratio of cannabinoid to amphiphilic carbohydrate compound is 1:10 to 3:10 g g−1, preferably wherein the ratio is around 1:5 g g−1.

### Claim 40 (depends on 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

A pharmaceutical composition according to any of claims 23 to 39 wherein the cannabidiol is stable for at least 4 weeks at 4° C.

### Claim 41 (depends on 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

A pharmaceutical composition according to any of claims 23 to 40 wherein the cannabidiol is stable for at least 4 weeks at 25° C.

### Claim 42 (depends on 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

A pharmaceutical composition according to any of claims 23 to 41 wherein the cannabidiol is least 99% recovered after being stored 4 weeks at 4° C.

### Claim 43

A pharmaceutical composition comprising GCPQ and a cannabinoid and one or more pharmaceutically acceptable excipients.

### Claim 44 (depends on 43)

A pharmaceutical composition according to claim 43 wherein the GCPQ has a palmitoylation level in the range 11-31 mole %.

### Claim 45 (depends on 43, 44)

A pharmaceutical composition according to claim 43 or 44 wherein the GCPQ has a quaternisation level in the range 8-17 mole %.

### Claim 46 (depends on 43, 44, 45)

A pharmaceutical composition according to any of claims 43 to 45 wherein the ratio of GCPQ:cannabinoid is between 1:1 and 1:10.

### Claim 47 (depends on 46)

A pharmaceutical composition according to claim 46 wherein the cannabinoid is selected from the group consisting of cannabidiol (CBD), cannabigerol (CBG), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabichromene (CBC) and combinations thereof.

### Claim 48 (depends on 47)

A pharmaceutical composition according to claim 47 wherein the cannabinoid is cannabidiol (CBD).

### Claim 49

A composition comprising GCPQ and a cannabinoid wherein the GCPQ has a palmitoylation level in the range 11-31 mole % and a quaternisation level in the range 8-17 mole %, and the ratio of GCPQ:cannabinoid is between 1:1 and 1:10.
